EDEVEN CM GEL TUBO 40G 2%+5%

OTHER C.M. GEL

active ingredients

(*) C.M.: modified composition for the elimination of an active ingredient (sodium heparine) Ed C.M. 1% + 5% gel 100 g gel contains: Active ingredients: Extract 1 g, Salicylate Dietilamina 5 g Ed C.M. 2% + 5% gel 100 g gel contains: Active ingredients: Extract 2 g, Salicylate Dietilamina 5 g Excipient with known effects: butylhydroxytolulo For the full list of excipients, see paragraph 6.1

Excellent

Lavender essence, nerolene essence, carboxypolymethylene, meglumine, propylene glycol, ethyl alcohol, sodium edetate, exyldecanol and laurate exyldecyldecyl, hetoxyglycol, butylhydroxytoluol, titanium dioxide, purified water.

Therapeutic indications

Minor trauma.

Contraindications

Hypersensitivity to active ingredients or any of the excipients listed in paragraph 6.1. Ed C.M. gel should not be used on open injuries (low), mucosa and skin areas treated with radiation. Do not use for prolonged periods without the advice of a doctor.

Population

Apply and spread a thin layer of Edeven C.M. gel on the skin of the area to be treated from 1 to 3 times a day. The safety and effectiveness of Edeven C.M. children under 12 years of age have not been established.

Conservation

Store at a temperature not exceeding 25°C.

Warnings

There is no risk of addiction and addiction. As a preparation for topical applications, its use must be exclusively external. Avoid contact with eyes. Prolonged use of topical products can give rise to awareness-raising phenomena. Important information about some excipients Ed C.M. contains butylhydroxytoluol (or butylhydroxytoluene) which can cause reactions on the localized skin (e.g. contact dermatitis) or irritation to the eyes and mucosa.

Interactions

No interactions with other medicines have been reported.

Effects

Immune system disorders: in rare cases hypersensitivity reactions such as redness, dequamation and dehydration of the skin may appear. Pathologies of skin and subcutaneous tissue: contact dermatitis. Reporting of suspicious adverse reactions. The reporting of suspicious adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at: www.agenziafarmaco.gov.it/content/come-segnalare-una-sospetta-reazione-avversa.

Overdosing

No overdose cases have been reported.

Pregnancy In case of pregnancy and during breastfeeding we do not recommend using Edeven C.M. gel if not under strict medical control. However, prolonged use (maximum 3 weeks) of the product should be avoided on extended skin areas during pregnancy. Food Avoid using the gel on the breast during breastfeeding.

Source: Farmadati